Tauopathies
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
Subtype terms (4)
More specific conditions that are subtypes of Tauopathies in the MeSH hierarchy.
- Alzheimer Disease
734 drugs (229 approved, 505 experimental)
- Corticobasal Degeneration
16 drugs (11 approved, 5 experimental)
- Diffuse Neurofibrillary Tangles with Calcification
- Supranuclear Palsy, Progressive
51 drugs (24 approved, 27 experimental)
Drugs by status
Phase 3 trials (1)
Phase 2 trials (8)
Phase 1 trials (6)
Other trials (2)
Organizations
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (1)